Overview

A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment

Status:
Not yet recruiting

Trial end date:
2024-11-30

Target enrollment:

Participant gender:

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in patients with degenerative mild cognitive impairment.

Phase:

Phase 4

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Collaborator:

Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies)

Treatments:

Choline